What's Happening?
Harbour BioMed, in collaboration with Windward Bio, has started dosing patients in the Phase 2 SIRIUS study of HBM9378/WIN378, a fully human ultra long-acting anti-TSLP antibody, for chronic obstructive pulmonary disease (COPD). The study is designed
to assess the safety, tolerability, and pharmacokinetics of the drug in patients with moderate-to-severe COPD. HBM9378/WIN378 is also under evaluation in a Phase 2/3 asthma study, with initial results anticipated in the latter half of 2026. The drug aims to be the first ultra long-acting anti-TSLP antibody available for asthma and COPD.
Why It's Important?
The launch of the Phase 2 SIRIUS study is a critical step in developing HBM9378/WIN378, which could significantly impact the treatment of COPD, a major global health challenge. Current therapies often fall short in managing the disease, leading to frequent exacerbations and hospitalizations. The introduction of a long-acting treatment could enhance patient care and reduce healthcare costs. This development also highlights the potential of HBM9378/WIN378 to become a pioneering therapy in the respiratory disease market, offering a new standard of care.
